Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

[Increased thromboembolic risk in atrial fibrillation and stroke prevention in women].

Undas A.

Przegl Lek. 2014;71(3):164-8. Review. Polish.

PMID:
25154215
2.

Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.

Taillandier S, Olesen JB, Clémenty N, Lagrenade I, Babuty D, Lip GY, Fauchier L.

J Cardiovasc Electrophysiol. 2012 Jul;23(7):708-13. doi: 10.1111/j.1540-8167.2011.02257.x. Epub 2012 Jan 23.

PMID:
22268375
3.

Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation.

Lip GY, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Popescu MI, Tica O, Hellum CF, Mortensen B, Tavazzi L, Maggioni AP.

Europace. 2015 Jan;17(1):24-31. doi: 10.1093/europace/euu155. Epub 2014 Jun 22.

PMID:
24957921
4.

Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.

Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS.

Circulation. 2005 Sep 20;112(12):1687-91. Epub 2005 Sep 12.

5.

Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.

Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):319-26. doi: 10.1161/CIRCEP.111.966713. Epub 2012 Feb 8.

6.

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators.

Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.

7.

Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.

Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P.

Circulation. 2004 Oct 19;110(16):2287-92. Epub 2004 Oct 11.

8.

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.

Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY.

J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18.

9.

Diagnosis and management of atrial fibrillation by primary care physicians in Italy : a retrospective, observational analysis.

Piccinocchi G, Laringe M, Guillaro B, Arpino G, Piccinocchi R, Nigro G, Calabrò P.

Clin Drug Investig. 2012 Nov;32(11):771-7. doi: 10.1007/s40261-012-0005-5.

10.

Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.

Galanis T, Merli GJ.

Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010. Review.

PMID:
23466965
11.

[Risk-adapted anticoagulation in atrial fibrillation in Germany, Austria and Switzerland - an analysis from the PREFER-in-AF study].

Steffel J, Gwechenberger M, Müller MW, Ammentorp B, Darius H, Kirchhof P.

Dtsch Med Wochenschr. 2015 Nov;140(23):e247-55. doi: 10.1055/s-0041-108996. Epub 2015 Nov 19. German.

PMID:
26583826
12.

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF).

Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, Zamorano JL.

Europace. 2014 Jan;16(1):6-14. doi: 10.1093/europace/eut263. Epub 2013 Oct 1.

13.

[Atrial fibrillation and thromboembolic events prevention. State of the art].

Matteoli S, Trappolini M, Chillotti FM.

Minerva Cardioangiol. 2001 Feb;49(1):1-13. Review. Italian.

PMID:
11279381
14.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
15.

Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.

Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D.

Thromb Haemost. 2009 May;101(5):938-42.

PMID:
19404548
16.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

Friberg L, Rosenqvist M, Lip GY.

Eur Heart J. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. Epub 2012 Jan 13.

PMID:
22246443
17.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

18.

[Prevention of thromboembolism in atrial fibrillation].

Aguiar C.

Rev Port Cardiol. 2012 Apr;31 Suppl 1:17-26. Portuguese.

PMID:
22541031
19.

Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.

Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312-8. doi: 10.1161/CIRCEP.111.967000. Epub 2012 Feb 7.

20.

Evaluation and management of atrial fibrillation.

Ali S, Hong M, Antezano ES, Mangat I.

Cardiovasc Hematol Disord Drug Targets. 2006 Dec;6(4):233-44. Review.

PMID:
17378769

Supplemental Content

Support Center